drugset / Trial / NCT04873115

Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,

NCT04873115

Phase 4 Unknown 80 enrolled Proveca Pharma Limited
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Double blind, placebo-controlled, randomised trial, multicentre in France with open-label tolerability phase. The double-blind placebo-controlled study duration will be scheduled for 3 months with the final visit of the double-blind period at D84. After the D84 assessment, patients will be invited to continue into a 6-month openlabel study extension (OLSE) with ex-Sialanar® patients continuing the treatment and ex-placebo patients starting Sialanar®

Timeline

Start
2021-05-10
Primary completion
2022-12-10
Completion
2023-06-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrronium Unknown Oral